Log in

Relevant bibliographies by topics / Glioblastoma Multiforme (WHO grade IV)

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'Glioblastoma Multiforme (WHO grade IV)'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Glioblastoma Multiforme (WHO grade IV).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Glioblastoma Multiforme (WHO grade IV)"

1

Litak, Jakub, Wiesława Grajkowska, Justyna Szumiło, et al. "PD-L1 Expression Correlated with p53 Expression in Pediatric Glioblastoma Multiforme." Brain Sciences 11, no. 2 (2021): 262. http://dx.doi.org/10.3390/brainsci11020262.

Full text

Abstract:

High-grade gliomas are infrequent in the pediatric population compared to adults, nevertheless, mortality and morbidity caused by malignant gliomas in this group of patients remain significant. PD-L1 and PD-1 Immune checkpoints (IC) molecules maintain immunological balance between activation and suppression. Eighteen patients with a histopathological diagnosis of pediatric glioblastoma multiforme (GBM, WHO IV) were studied. In total, PD-L1 expression was detected in 8 patients (44%). The molecular aspect of IC and immunotherapy targeted on PD-1/PD-L1 axis in pediatric population may be a promi

APA, Harvard, Vancouver, ISO, and other styles

2

Faulkner, Kalli, Blythe Bowman, and Jeffrey Sosnowski. "Glioblastoma Multiforme (Gliosarcoma) WHO Grade IV With Osteosarcomatous Differentiation: A Case Study." American Journal of Clinical Pathology 138, suppl 1 (2012): A005. http://dx.doi.org/10.1093/ajcp/138.suppl1.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Sánchez-Prieto, Lucía, and Ángel M. Cuesta. "Immunotherapy in action: Innovative strategies against glioblastoma multiforme." Anales de la Real Academia Nacional de Farmacia, no. 91(01) (March 31, 2025): 45–65. https://doi.org/10.53519/analesranf.2025.91.01.02.

Full text

Abstract:

Glioblastoma multiforme (GBM) is the most common type of brain tumor in adults, with an annual incidence around 1/33,330 and a prevalence estimated at 1/100,000. This is the reason why Orphanet has cataloged it as a rare disease. Moreover, it is classified by the World Health Organization (WHO) as astrocytoma grade IV. It is well known to be an aggressive tumor, and this is why, although its treatment combines surgery, radiotherapy, and chemotherapy, the life expectancy of those who suffer from it doesn’t reach 14 months. The bad efficiency of the therapy is due to the molecular characteristic

APA, Harvard, Vancouver, ISO, and other styles

4

Delgado, Benjamin J., Leila Moosavi, Ericka Rangel, et al. "An Unusual Presentation of Spinal Giant Cell Glioblastoma in a 21-Year-Old Female." Journal of Investigative Medicine High Impact Case Reports 7 (January 2019): 232470961986825. http://dx.doi.org/10.1177/2324709619868255.

Full text

Abstract:

Primary spinal cord giant cell glioblastoma multiforme of the thoracic spinal cord is a rarely-diagnosed primary spinal cord tumor in comparison to neoplasms in intracranial locations. In this article, we highlight a young adult who was diagnosed with intramedullary giant cell glioblastoma, IDH wild-type, World Health Organization grade IV/IV of the thoracic spinal cord. This case report describes the treatment approach with a postsurgical combination of radiation therapy and temozolomide, which resulted in the patient to return to her baseline of health only to later develop neurological symp

APA, Harvard, Vancouver, ISO, and other styles

5

Shawki, Omar, Salman Shaikh, Soumya Mukherjee, Hussien El-Maghraby, and Ronan Dardis. "SURVIVAL OVER A DECADE IN A CASE OF GLIOBLASTOMA." Neuro-Oncology 25, Supplement_3 (2023): iii21. http://dx.doi.org/10.1093/neuonc/noad147.092.

Full text

Abstract:

Abstract AIMS Glioblastoma multiforme is the most aggressive type of primary brain tumours, but there is a small percentage of patients who have a long-term survival and some exceptional cases who survive decades after surgical removal of tumour along with adjuvant therapy. METHOD In 2011, a 40-year-old man, presented with headaches & confusion and underwent gliolan guided resection of a right frontal glioblastoma WHO grade IV. He received 30# of 60Gy Radiotherapy with TMZ. Chemotherapy was continued with interval scans in 2016 and 2018 showing stable disease. MRI scan in October 2022 show

APA, Harvard, Vancouver, ISO, and other styles

6

Lagiou, Anthoula, Ioannis Papagiannopoulos, Nikoletta Margari, and Georgios Vasilopoulos. "Epidemiological - clinical features of primary malignant brain tumors of patients who underwent surgical resection and / or radiotherapy." Health & Research Journal 1, no. 1 (2015): 56. http://dx.doi.org/10.12681/healthresj.19286.

Full text

Abstract:

The aim of the present study was to describe the demographic characteristics of patients diagnosed with primary brain tumor, the clinical features and prognostic indicators of disease progression and treatment they received.Methods: A retrospective descriptive study was conducted on a convenience sample of 47 patients who attended the radiotherapeutic department of General Hospital of Athens over three years, from May 2011 until May 2014.For analysis used the statistical program SPSS 18.0.Results: 59.6% of patients were male and 40.4% of patients were between 61 and 69 years. 85.1% of patients

APA, Harvard, Vancouver, ISO, and other styles

7

Michael, Justin S., Bong-Seop Lee, Miqin Zhang, and John S. Yu. "Nanotechnology for treatment of glioblastoma multiforme." Journal of Translational Internal Medicine 6, no. 3 (2018): 128–33. http://dx.doi.org/10.2478/jtim-2018-0025.

Full text

Abstract:

Abstract Glioblastoma multiforme (GBM), a grade IV astrocytoma as defined by the World Health Organization (WHO) criteria, is the most common primary central nervous system tumor in adults. After treatment with the current standard of care consisting of surgical resection, concurrent temozolomide (TMZ), and radiation, the median survival is only 15 months. The limited and less-effective treatment options for these highly aggressive GBMs call for the development of new techniques and the improvement of existing technologies. Nanotechnology has shown promise in treating this disease, and some na

APA, Harvard, Vancouver, ISO, and other styles

8

Liu, Zhongyu, Zhiqiang Yao, Chao Li, Yicheng Lu, and Chunfang Gao. "Gene Expression Profiling in Human High-Grade Astrocytomas." Comparative and Functional Genomics 2011 (2011): 1–10. http://dx.doi.org/10.1155/2011/245137.

Full text

Abstract:

Diffuse astrocytoma of (WHO grade II) has a tendency to progress spontaneously to anaplastic astrocytoma (WHO grade III) and/or glioblastoma (WHO grade IV). However, the molecular basis of astrocytoma progression is still poorly understood. In current study, an essential initial step toward this goal is the establishment of the taxonomy of tumors on the basis of their gene expression profiles. We have used gene expression profiling, unsupervised (hierarchal cluster (HCL) and principal component analysis (PCA)) and supervised (prediction analysis for microarrays (PAM)) learning methods, to demo

APA, Harvard, Vancouver, ISO, and other styles

9

Woźnicki, Paweł, Dorota Bartusik-Aebisher, Agnieszka Przygórzewska, and David Aebisher. "Immunological Insights into Photodynamic Therapy of Glioblastoma Multiforme." Molecules 30, no. 15 (2025): 3091. https://doi.org/10.3390/molecules30153091.

Full text

Abstract:

The Gliomas account for 81% of all malignant central nervous system tumors and are classified by WHO into four grades of malignancy. Glioblastoma multiforme (GBM), the most common grade IV glioma, exhibits an extremely aggressive phenotype and a dismal five-year survival rate of only 6%, underscoring the urgent need for novel therapeutic approaches. Immunotherapy has emerged as a promising strategy, and photodynamic therapy (PDT) in particular has attracted attention for its dual cytotoxic and immunostimulatory effects. In GBM models, PDT induces immunogenic cell death characterized by the rel

APA, Harvard, Vancouver, ISO, and other styles

10

Syed, Aaqid Siraj, Sanjana Sehgal, Sanjeev K. Pandey, Brijesh K. Tiwari, Ranjit Kumar, and Meenu Gupta. "Primary spinal glioblastoma multiforme: a case report." International Surgery Journal 11, no. 6 (2024): 1023–26. http://dx.doi.org/10.18203/2349-2902.isj20241410.

Full text

Abstract:

Spinal cord glioblastoma multiforme (GBM) is an uncommon disease within spinal tumours. According to our review of literature, less than 200 patients have been reported so far. Here we highlight the case of a 35 year female who complained of mild and intermittent lower back pain that radiates to bilateral thighs and was associated with tingling and numbness over both feet. The patient was evaluated and operated elsewhere with L1-L2 laminectomy and micro-surgical excision and it was reported as a case of myxopapillary ependymoma. However, immunohistochemical (IHC) stains were positive for GBM g

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Glioblastoma Multiforme (WHO grade IV)"

1

Schäfer, Julia Astrid. "Glutamatstoffwechsel in Glioblastoma multiforme WHO-Grad IV." 2017. https://ul.qucosa.de/id/qucosa%3A20902.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Glioblastoma Multiforme (WHO grade IV)"

1

Mammoser, Aaron. Primary and Secondary Glioblastoma. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199937837.003.0127.

Full text

Abstract:

Glioblastoma, formerly glioblastoma multiforme, is synonymous with WHO grade IV astrocytoma and is the most commonly diagnosed astrocytoma; it carries with it significant clinical, histologic, and molecular heterogeneity, with subtypes of the tumor and important new mutations associated with it characterized over the previous decade. Gene expression profiling has identified four tumor subgroups associated with specific mutational patterns, age of onset, and prognosis. The discovery of isocitrate dehydrogenase (IDH) mutations has led to further delineation between primary and secondary glioblas

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Glioblastoma Multiforme (WHO grade IV)"

1

Weis, Serge, Michael Sonnberger, Andreas Dunzinger, et al. "Gliosarcoma WHO Grade IV-Giant Cell Glioblastoma WHO Grade IV." In Imaging Brain Diseases. Springer Vienna, 2019. http://dx.doi.org/10.1007/978-3-7091-1544-2_55.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Quinones, Addison, and Anne Le. "The Multifaceted Glioblastoma: From Genomic Alterations to Metabolic Adaptations." In The Heterogeneity of Cancer Metabolism. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-65768-0_4.

Full text

Abstract:

AbstractGlioblastoma multiforme (GBM) develops on glial cells and is the most common as well as the deadliest form of brain cancer. As in other cancers, distinct combinations of genetic alterations in GBM subtypes induce a diversity of metabolic phenotypes, which explains the variability of GBM sensitivity to current therapies targeting its reprogrammed metabolism. Therefore, it is becoming imperative for cancer researchers to account for the temporal and spatial heterogeneity within this cancer type before making generalized conclusions about a particular treatment’s efficacy. Standard therap

APA, Harvard, Vancouver, ISO, and other styles

3

Adamson D. Cory, Rasheed B. Ahmed K., McLendon Roger E., and Bigner Darell D. "Central nervous system." In Translational Pathology of Early Cancer. IOS Press, 2012. https://doi.org/10.3233/978-1-61499-024-6-193.

Full text

Abstract:

Several different types of tumors, benign and malignant, have been identified in the central nervous system (CNS). The prognoses for these tumors are related to several factors, such as the age of the patient and the location and histology of the tumor. In adults, about half of all CNS tumors are malignant, whereas in pediatric patients, more than 75% are malignant. For most benign CNS tumors that require treatment, neurosurgeons can offer curative resections or at least provide significant relief from mass effect. Unfortunately, we still lack effective treatments for most primary and secondar

APA, Harvard, Vancouver, ISO, and other styles

4

Nistér, M., L. Uhrbom, G. Hesselager, and B. Westermark. "Glial Tumors of the CNS." In Glial Cell Development basic principles and clinical relevance second edition. Oxford University PressOxford, 2001. http://dx.doi.org/10.1093/oso/9780198524786.003.0021.

Full text

Abstract:

Abstract Glial tumors are classified into certain major types (Kleihues and Cavenee, 1997; D.D.Bigner et al.,1998). They have their peak incidences at different ages and show different degrees of differentiation. According to the WHO classification (Kleihues et al.,1993, 1995) they are graded from I to IV, where grade I comprises virtually benign tumors and grade IV highly malignant ones (Table 21.1). We have chosen here to focus on the most frequent types, such as low-grade diffuse astrocytoma (WHO grade II), anaplastic astrocytoma (WHO grade III), glioblastoma (WHO grade IV), pilocytic astro

APA, Harvard, Vancouver, ISO, and other styles

5

Y. Shan, Frank, Dachun Zhao, Carlos A. Tirado, et al. "Glioblastomas: Molecular Diagnosis and Pathology." In Glioblastoma - Current Evidences [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.105472.

Full text

Abstract:

Glioblastoma (GBM) is a fatal human brain tumor of grade IV/4 by WHO classification, with a very poor prognosis. At the molecular level and clinical, GBM has at least two types, primary and secondary. Each has a different tumorigenesis and clinical presentation. In this chapter, some major molecular biomarkers and diagnostic hallmarks of GBM will be reviewed and discussed.

APA, Harvard, Vancouver, ISO, and other styles

6

Chen, Liam. "CNS High Grade Glioma." In Central Nervous System Tumors. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.99984.

Full text

Abstract:

Since the publication of the 2016 edition of the WHO Classification of CNS Tumors, advances in neuropathology have enhanced our understanding of the molecular underpinnings of CNS tumors, providing new elements to refine their classification and improve pathological diagnosis of these neoplasms. This chapter will review the highlights of the updated recommendations which provide guidance for how even in the absence of histopathological characteristics of the highest malignancy grade, molecular markers can be used to reach a diagnosis of glioblastoma, IDH–wild-type or astrocytoma, IDH-mutant, g

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Glioblastoma Multiforme (WHO grade IV)"

1

Check, Jerome H., Carrie Wilson, and Diane Check. "Abstract 485: Evidence that mifepristone, a progesterone receptor antagonist, can cross the blood brain barrier and provide palliative benefits for glioblastoma multiforme grade IV." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-485.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Sharma, Puja, Brian Koons, and Amrinder S. Nain. "Blebbing Dynamics, Single Cell Force Measurements, and the Influence of Cytochalasin D on Glioblastoma Multiforme Cells Using STEP Fibers." In ASME 2013 2nd Global Congress on NanoEngineering for Medicine and Biology. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/nemb2013-93105.

Full text

Abstract:

Classified as a grade IV tumor of the central nervous system, Glioblastoma multiforme (GBM) arises from the glia. A poor understanding of tumor metastasis and limited treatment options have led to increase in deaths of patients suffering from GBM. Studying glioma behavior using aligned structures that mimic native glioblastoma metastatic path is challenging. In this study, we utilize a previously described non-electrospinning platform to manufacture aligned 3D structures called STEP nanonets that not only allows the study of individual cell-nanofiber interaction, but also allows the calculatio

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!